Clotting, microembolism, and inhibition of fibrinolysis in adult respiratory distress.
Clinical and autopsy studies have shown an association between clotting, microembolism, and inhibition of fibrinolysis and respiratory distress after trauma or sepsis. Prophylaxis and treatment with the aim of decreasing the deposition of fibrin in the lungs were associated with a large decrease in the incidence and death rate of this syndrome. Small fibrin degradation products (peptides) are accumulated in the lungs and are only slowly cleared from this organ, especially during states of inhibition of fibrinolysis. These peptides may contribute to the pulmonary damage in several ways. As well as having a direct effect on the endothelium, they act by interfering with other vasoactive substances as bradykinin, histamine, and products of the arachidonic acid cascade. Products of the cyclooxygenase pathway such as thromboxane A2 play a major role in early microembolism, whereas lipoxygenase products seem to be involved in later stages. Pulmonary microembolism thus seems to be one important, but certainly not the only, pathogenetic factor in acute "idiopathic" respiratory failure. Other factors, such as pulmonary contusion, aspiration of gastric contents or blood, or oxygen toxicity, might well be contributory in some cases. Pulmonary microemboli containing fibrin and leukocytes are probably also involved as contributory agents in some cases in the large group of acute respiratory failures due to "known factors."
D000418:Albumins / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic; D003911:Dextrans / Q000494:pharmacology / Q000627:therapeutic use; D004285:Dogs; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000098:blood supply / Q000473:pathology / Q000503:physiopathology; D011655:Pulmonary Embolism / Q000150:complications* / Q000401:mortality; D011897:Random Allocation; D051381:Rats; D012128:Respiratory Distress Syndrome / Q000503:physiopathology*; D013577:Syndrome; D013917:Thrombin / Q000494:pharmacology; D013997:Time Factors
D000418:Albumins; D003911:Dextrans; D005337:Fibrin; D006493:Heparin; D013917:Thrombin